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Abstract 
Purpose: To describe a case of bilateral cytomegalovirus retinitis (CMVR) in an 
immunocompromised infant.  
Methods: A 4-month-old male infant with severe combined immunodeficiency syndrome 
was examined for the presence of CMVR. Ocular involvement was recorded and 
monitored by digital imaging.  
Results: The child had bilateral CMVR, with a fine granular pattern, present both in the 
peripheral retina and posterior pole. There was no vitritis. The active areas of retinitis 
progressively resolved with intravenous ganciclovir treatment. At the 3-month follow-up 
examination, no recurrence was observed.  
Conclusion: Ganciclovir treatment was effective in this case. The prognosis depends on 
rapid institution of effective antiviral therapy and on a patient’s systemic 
immunocompetence. 
 
Introduction 
Cytomegalovirus (CMV) is the most frequent cause of congenital and perinatal viral 
infections in humans [1]. The incidence of CMV retinitis (CMVR) in children with 
systemic disease has been reported to be as high as 25% in infants with severely 
symptomatic congenital CMV and 1% in asymptomatic congenitally infected infants [2]. 
CMVR is the most common opportunistic infection in the eyes of adults with HIV, and 
before combination therapy 20–40% of these patients were affected. In contrast, CMVR 
has been reported in only 5% of children with HIV [3]. Other immunosuppressive 
conditions associated with CMVR in children are severe combined immunodeficiency Case Rep Ophthalmol 2011;2:238–242 
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syndrome (SCID), acquired immunodeficiency syndrome after bone marrow or renal 
transplantation, and chemotherapy [4]. The occurrence of CMVR is less common in 
children than in adults. Only few cases have been reported in children. We describe a case 
of an immunocompromised infant with acquired systemic CMV infection who developed 
bilateral CMVR. 
Case Report 
A 4-month-old male infant with a recent diagnosis of SCID developed an acute CMV infection with 
interstitial pneumonitis and colitis. Initial PCR detection of CMV DNA in serum was positive, with 
5,800 copies/ml. The patient was referred to our institute for the evaluation of possible CMVR. He was 
admitted to a pediatric intensive care unit, and treatment for all the systemic problems described was 
started, including intravenous immunoglobulin once a week along with intravenous ganciclovir (10 
mg/kg/day). 
He was examined 1 week after the initiation of treatment. Fundus photographs were made with a 
RetCam 120 wide-field digital fundus camera (Massie Labs, Dublin, Calif., USA). Our patient had 
bilateral active CMVR with multiple granular whitish lesions, present in the peripheral retina and 
posterior pole (fig. 1). Progressive pigment deposition was found around the lesions from posterior to 
anterior, and evolved to chorioretinal scarring (fig. 2, fig. 3). Reevaluation was done weekly until total 
resolution of the active retinal lesions could be observed. The patient was followed up for 3 months and 
no recurrence was found. Treatment with intravenous ganciclovir (10 mg/kg/day) was continued during 
hospitalization (12 weeks). The child was then transferred to another hospital unit to undergo a bone 
marrow transplantation, which is the treatment of choice for SCID. 
When he was discharged, the patient’s IgG levels were 841 mg/dl and there were 900 copies/ml of 
CMV DNA. Ganciclovir dosage was not reduced due to still active systemic CMV infection. 
Discussion 
The disease patterns of CMVR are quite different in infants compared to adults. 
Baumal et al. [5], in a review of 9 children with CMVR, found that it was bilateral in 89% 
and involved the posterior pole in at least 1 eye of all 9 patients. Wren et al. [3] recently 
confirmed this pattern of presentation. In our case, there was bilateral involvement with 
lesions in the posterior pole. The fundal appearances may vary from subtle white flecks, 
giving a granular appearance, to more florid presentations with white infiltrates 
accompanied by hemorrhage [3]. Congenital infection is typically less hemorrhagic than 
perinatal infection acquired by immunocompromised children. However, our case had 
only multifocal granular lesions, without hemorrhage or vitritis. Factors that may 
contribute to the differences in disease expression are the state of the immune system, the 
type of exposure to the virus, and primary infection/reactivation of the latent virus. 
Prompt treatment is probably the most important prognostic factor; however, the 
optimal therapy for CMVR in children has not yet been defined [1]. Ganciclovir has 
potential toxicity as it can cause neutropenia, inhibit spermatogenesis and induce possible 
carcinogenic effects in animals. Long-term safety data regarding its use in infants are not 
yet available [2]. Most clinical trials with ganciclovir have shown reduced hearing loss and 
regression of retinitis. The use of oral valganciclovir as an alternative therapy is currently 
under evaluation since its bioavailability equals that of intravenous ganciclovir and it does 
not have the associated comorbidities of prolonged hospital stay and intravenous 
administration [6, 7]. Ohta et al. [8] showed the efficacy and safety of foscarnet for Case Rep Ophthalmol 2011;2:238–242 
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treating pediatric patients with CMVR. Current treatment for CMV infection is 
intravenous ganciclovir for 3–6 weeks; however, there are still doubts regarding which 
infants should be treated and for how long. In immunocompromised infants with 
symptomatic CMV infection, treatment should be initiated as soon as possible to prevent 
long-term systemic or visual morbidity. 
In our case, treatment was based on a defective immune system, viremia and organ 
damage. CMVR was detected 1 week after starting treatment and, therefore, the lesions 
showed some initial scarring characteristics. We believe that prompt treatment was 
decisive to prevent progression to a more serious form of chorioretinitis. 
Disclosure Statement 
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Fig. 1. Right fundus showing granular whitish lesions, two in the retinal periphery and one in the 
posterior pole. The largest lesion already shows some pigmentation in the periphery. Left fundus 
showing granular whitish lesions in the posterior pole. 
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Fig. 2. Two weeks after initiating treatment, the right and left fundus showed progressive pigmentation 
of the lesions. 
 
 
 
Fig. 3. One month after treatment, right and left fundus images showed total resolution of the active 
lesions, with the formation of chorioretinal scars. 
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